---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-108409"
form_type: "8-K"
ticker: "LRMR"
cik: "0001374690"
company_name: "Larimar Therapeutics, Inc."
filed_at: "2025-08-14T23:59:59+00:00"
generated_at: "2026-05-17T12:58:20.425747+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Larimar Therapeutics reports Q2 2025 net loss $26.2M; BLA for nomlabofusp on track for Q2 2026

## Summary
- Net loss $26.2M ($0.41/share) vs $21.6M ($0.34) in Q2 2024; R&D expenses $23.4M, up from $19.7M.
- Cash, equivalents, marketable securities $138.5M at June 30; pro forma $203.6M incl. $65.1M July offering; runway into Q4 2026.
- FDA recommends safety database: 30+ participants on 50 mg for 6 months, subset of 10 for 1 year.
- Initial 50 mg open-label and adolescent PK run-in data expected September 2025.
- Global Phase 3 sites identified in US, EU, UK, Canada, Australia; patient recruitment to begin later 2025.

## SEC filing metadata
- accession: 0000950170-25-108409
- form_type: 8-K
- ticker: LRMR
- cik: 0001374690
- company_name: Larimar Therapeutics, Inc.
- filed_at: 2025-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1374690/000095017025108409/0000950170-25-108409-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1374690/000095017025108409/lrmr-20250814.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-108409
- JSON: https://secwatch.observer/filing/0000950170-25-108409.json
- Plain text: https://secwatch.observer/filing/0000950170-25-108409.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.